The goal of this work is to develop, refine, and pilot test an electronic visit (e-visit) to: 1) deliver smoking cessation treatment to adults at risk for COPD and 2) to improve rates of COPD early detection and accurate diagnosis. We will conduct a pilot RCT of the COPD/smoking cessation e-visit as compared to treatment as usual (TAU), with primary objective to provide effect size estimates for a larger RCT.
Although smoking cessation interventions are increasingly moving toward remote delivery, remote assessment of smoking behavior faces one key methodological limitation: the need for biochemical verification of smoking status. To address this need, we herein will develop a remote CO data capture system through which a smartphone-enabled CO monitor (iCO™ Smokerlyzer) is integrated with REDCap. Subsequently, we will conduct a remote feasibility trial with smokers to examine: a) validity of the remote iCO™/REDCap data capture system as compared to gold-standard methods for biochemical verification of smoking and b) compliance with remote CO monitoring via the iCO™/REDCap system as applied both to episodic (i.e., once per week) and granular (i.e., once per day) data collection.
The goal of this study is to develop, refine, and complete preliminary feasibility testing of a smoking cessation electronic visit (e-visit) for implementation in primary care/family medicine. We will conduct a feasibility RCT (n=90) of the smoking cessation e-visit as compared to treatment as usual (TAU), delivered via primary care, with primary objective to provide effect size estimates for a larger RCT. Primary outcomes cluster around: 1) treatment feasibility, 2) treatment acceptability, 3) treatment satisfaction, 4) evidence-based cessation treatment utilization, and 5) cessation-related outcomes (quit attempt incidence, abstinence). We hypothesize that participants randomized to the e-visit condition as compared to those randomized to the TAU condition will have higher rates of cessation treatment utilization (medications, counseling) and superior cessation-related outcomes.